Skip to main content

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Active, not recruiting · Phase 2 · NCT05104476

Conditions: Multiple System Atrophy

At a glance

Research payments reported, 2025
$866,957
U.S. investigators named
14
Sites paid
14
Planned or actual enrollment
64

About the trial

Sponsor
H. Lundbeck A/S
Tested
Lu AF82422 (drug), Placebo (drug)
Dates
Started 2021-11-16; completion 2028-03-07
Results posted
Yes

To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)

Industry funding

H. Lundbeck A S reported $866,957 in research payments for this study in 2025 (243 payments).

Products named: Brintellix

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Parkinsons Disease and Movement $160,033
  • Mayo Clinic College of Medicine and Science $149,213
  • UCSF Medical Center, CA $90,160
  • University of Pittsburgh Physicians $75,612
  • The PArkinsons and Movement Disorder Institute $56,160
  • Rush University Medical Center $54,334
  • Unehealth $54,285
  • Northshore University Healthsystem $50,262
  • University of Florida $36,070
  • Trustees of the University of Pennsylvania $34,338
  • New York University School of Medicine $31,614
  • Trustees of Columbia University in The City of New York $29,681
  • Beth Israel Deaconess Medical Center, MA $24,961
  • Cenexel Rocky Mountain Clinical Research LLC $20,234

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.